Multiple Sclerosis | ChartTrends | US | 2014
The syndicated ChartTrends: Multiple Sclerosis (US) report allows clients to better understand the actual treatment of multiple sclerosis (MS) with disease-modifying therapies (DMTs) through comparison of what physicians self-report about disease management to what occurs at the patient level. Through an in-depth review of charts from patients currently treated with Aubagio, Avonex, Betaseron, Copaxone, Gilenya, Rebif, Tecfidera, and Tysabri, details such as product initiation, switching, monitoring, and a host of tests and patient demographic variables help define patient types and identify drivers of therapy choice. The report also evaluates physician receptivity to products in development for the treatment of MS, and identifies potential characteristics of patient candidates for each product.
